Study Reveals Major Drawback to The Health Benefits of Fasting
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 15, 2024
The human body can survive without food for some time before starvation risks causing significant harm to the body.
Sun.Dec 15, 2024
241 
Risk adjusted net present value: What is the current valuation of Merck’s Enlicitide decanoate?
Pharmaceutical Technology
DECEMBER 15, 2024
Enlicitide decanoate is a peptide commercialized by Merck, with a leading Phase III program in Hypercholesterolemia.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Expirations for the Week of December 15, 2024
Drug Patent Watch
DECEMBER 15, 2024
REMODULIN (treprostinil) United therap Patent: 10,076,505 Expiration: Dec 16, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s LY-3541860?
Pharmaceutical Technology
DECEMBER 15, 2024
LY-3541860 is a monoclonal antibody commercialized by Eli Lilly and Co, with a leading Phase II program in Relapsing Multiple Sclerosis (RMS).
Bridging Innovation & Patient Care: The Growing Role of AI
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Ayush Ministry amends D&C Act to add Homoeopathy, Sowa Rigpa books and Pharmacopoeias
AuroBlog - Aurous Healthcare Clinical Trials blog
DECEMBER 15, 2024
The Union Ministry of Ayush has notified amendment to the Drugs and Cosmetics Act, 1940 adding French Homoeopathic Pharmacopoeia and the European Pharmacopoeia under the standards on which the imports and manufacturing of homoeopathic drugs will be allowed in the country.
Risk adjusted net present value: What is the current valuation of Alto Neuroscience’s Agomelatine?
Pharmaceutical Technology
DECEMBER 15, 2024
Agomelatine is a small molecule commercialized by Alto Neuroscience, with a leading Phase II program in Major Depressive Disorder.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s Amycretin?
Pharmaceutical Technology
DECEMBER 15, 2024
Amycretin is a synthetic peptide commercialized by Novo Nordisk, with a leading Phase II program in Obesity.
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Eloralintide?
Pharmaceutical Technology
DECEMBER 15, 2024
Eloralintide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase II program in Obesity.
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sipavibart?
Pharmaceutical Technology
DECEMBER 15, 2024
Sipavibart is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Coronavirus Disease 2019 (COVID-19).
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s RYZ-101?
Pharmaceutical Technology
DECEMBER 15, 2024
RYZ-101 is a synthetic peptide commercialized by Bristol-Myers Squibb, with a leading Phase III program in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET).
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-6234?
Pharmaceutical Technology
DECEMBER 15, 2024
AZD-6234 is a synthetic peptide commercialized by AstraZeneca, with a leading Phase I program in Obesity.
Risk adjusted net present value: What is the current valuation of Pfizer’s Ibuzatrelvir?
Pharmaceutical Technology
DECEMBER 15, 2024
Ibuzatrelvir is a small molecule commercialized by Pfizer, with a leading Phase II program in Coronavirus Disease 2019 (COVID-19).
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
Pharmaceutical Technology
DECEMBER 15, 2024
NBI-1076986 is a small molecule commercialized by Neurocrine Biosciences, with a leading Phase I program in Movement Disorders.
Risk adjusted net present value: What is the current valuation of Cartesian Therapeutics’s Descartes-08?
Pharmaceutical Technology
DECEMBER 15, 2024
Descartes-08 is a gene-modified cell therapy commercialized by Cartesian Therapeutics, with a leading Phase II program in Myasthenia Gravis.
Risk adjusted net present value: What is the current valuation of Compass Pathways’s CTX-471?
Pharmaceutical Technology
DECEMBER 15, 2024
CTX-471 is a monoclonal antibody commercialized by Compass Pathways, with a leading Phase I program in Head And Neck Cancer.
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s BMS-986446?
Pharmaceutical Technology
DECEMBER 15, 2024
BMS-986446 is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase II program in Alzheimer's Disease.
Risk adjusted net present value: What is the current valuation of GSK’s GSK-3858279?
Pharmaceutical Technology
DECEMBER 15, 2024
GSK-3858279 is a monoclonal antibody commercialized by GSK, with a leading Phase II program in Osteoarthritis Pain.
Risk adjusted net present value: What is the current valuation of Simcere Pharmaceutical Group’s (Dexborneol + Edaravone)?
Pharmaceutical Technology
DECEMBER 15, 2024
(Dexborneol + Edaravone) is a small molecule commercialized by Simcere Pharmaceutical Group, with a leading Phase I program in Acute Ischemic Stroke.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Risk adjusted net present value: What is the current valuation of Otsuka’s Zipalertinib?
Pharmaceutical Technology
DECEMBER 15, 2024
Zipalertinib is a small molecule commercialized by Otsuka, with a leading Phase III program in Non-Small Cell Lung Cancer.
Risk adjusted net present value: What is the current valuation of Vertex Pharmaceuticals’s Vanzacaftor + Deutivacaftor + Tezacaftor?
Pharmaceutical Technology
DECEMBER 15, 2024
Vanzacaftor + Deutivacaftor + Tezacaftor is a small molecule commercialized by Vertex Pharmaceuticals, with a leading Pre-Registration program in Cystic Fibrosis.
Risk adjusted net present value: What is the current valuation of GSK’s GSK-3810109?
Pharmaceutical Technology
DECEMBER 15, 2024
GSK-3810109 is an antibody commercialized by GSK, with a leading Phase II program in Human Immunodeficiency Virus (HIV) Infections (AIDS).
Risk adjusted net present value: What is the current valuation of Arvinas’s Vepdegestrant?
Pharmaceutical Technology
DECEMBER 15, 2024
Vepdegestrant is a small molecule commercialized by Arvinas, with a leading Phase III program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Risk adjusted net present value: What is the current valuation of Atara Biotherapeutics’s ATA-3219?
Pharmaceutical Technology
DECEMBER 15, 2024
ATA-3219 is a gene-modified cell therapy commercialized by Atara Biotherapeutics, with a leading Phase I program in Diffuse Large B-Cell Lymphoma;Mantle Cell Lymphoma;Follicular Lymphoma;B-Cell Non-Hodgkin Lymphoma.
Let's personalize your content